Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study.

ABSTRACT:

Background

In the LATITUDE study (ClinicalTrials.gov, NCT01715285), compared with placebos, abiraterone acetate plus prednisone (AAP) with androgen deprivation therapy (ADT) provided significant overall survival (OS) benefit in high-risk metastatic castration-sensitive prostate cancer (mCSPC) patients. It is controversial whether survival benefits would remain if all patients in the placebo group subsequently received life-extending therapies.

Objective

To estimate treatment effect in the case of all patients in the placebo group receiving life-extending subsequent therapies.

Design setting and participants

A post hoc analysis of LATITUDE final-analysis data was carried out (setting and participants have been reported previously).

Intervention

AAP or placebos p

SUBMITTER: Koroki Y 

PROVIDER: S-EPMC8783036 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature